1stOncology™: Cancer Intelligence Service – Page 11960 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Seelos Therapeutics Announces Pricing of $4.5 Million Public Offering of Common Stock

On March 11, 2020 Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, reported the pricing of an underwritten public offering of 7,500,000 shares of its common stock, at a price to the public of $0.60 per share (Press release, Apricus Biosciences, MAR 11, 2020, View Source [SID1234555499]). In addition, the Company granted the underwriters a 45-day option to purchase up to 1,125,000 additional shares of its common stock to cover over-allotments, if any. All of the shares of common stock in the offering are being sold by Seelos.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Benchmark Company is acting as sole book-running manager for the offering.

Seelos anticipates the aggregate net proceeds from the offering will be approximately $3.9 million, after deducting the underwriting discounts and commissions and estimated offering expenses payable by Seelos, but excluding any exercise of the underwriters’ option to purchase additional shares of common stock. Seelos intends to use the net proceeds from the offering for general corporate purposes and to advance the development of its product candidates. This offering is expected to close on or about March 16, 2020, subject to the satisfaction of customary closing conditions.

The securities described above were offered by Seelos pursuant to a shelf registration statement on Form S-3 (File No. 333-221285) previously filed with the Securities and Exchange Commission (the "SEC") on November 2, 2017, amended on December 1, 2017 and declared effective by the SEC on December 7, 2017. The securities may be offered only by means of a prospectus. A preliminary prospectus supplement and the accompanying prospectus relating to and describing the offering has been filed with the SEC. Electronic copies of the preliminary prospectus and, when available, copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained by visiting the SEC’s website at www.sec.gov or by contacting The Benchmark Company, LLC, Attn: Prospectus Department, 150 E. 58th Street, 17th floor, New York, NY 10155, by calling (212) 312-6700 or by e-mail at [email protected].

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

Fight Colorectal Cancer Receives Grant from Exact Sciences to Launch Program Aimed at Reducing Patient Barriers to Colorectal Cancer Screening

On March 11, 2020 Fight Colorectal Cancer (Fight CRC) reported the launch of the Catalyst State-by-State Advocacy Program, with the help of an unrestricted grant from Exact Sciences (Press release, Fight CRC, MAR 11, 2020, https://www.prnewswire.com/news-releases/fight-colorectal-cancer-receives-grant-from-exact-sciences-to-launch-program-aimed-at-reducing-patient-barriers-to-colorectal-cancer-screening-301021163.html [SID1234555441]). The new initiative will provide funding and expertise to help advance legislation and policies geared toward increasing participation with colorectal cancer screening.

Colorectal cancer is the second-leading cause of cancer death in the U.S. in men and women combined1 even though it can be effectively prevented or detected early and treated through screening. One in three adults ages 50 to 75 are not screened as recommended according to American Cancer Society (ACS) guidelines.2 Colorectal cancer is also on the rise in younger adults,3 prompting ACS to lower the recommended screening age to 45. ACS also stressed the importance of getting screened and following all positive noninvasive screening tests with a colonoscopy.4 Cost is a well-known barrier to screening and often patients don’t complete a follow-up colonoscopy because they fear a bill. According to a large study in one health system, patients who do not follow up on an abnormal test result are seven times more likely to die from colorectal cancer than those who complete the entire screening process.5

In the program’s first year, Fight CRC will award four states Catalyst grant funding and provide technical assistance to support two primary objectives:

Ensure that insurance coverage is in place for colorectal cancer screening starting at age 45, consistent with ACS guidelines.
Remove cost barriers for patients who need a follow-up colonoscopy, following a positive first-line screening test.
"Fight CRC is thrilled to launch the Catalyst State-by-State Advocacy Program and begin working at the state level to implement policy that will increase access to colorectal cancer screening. We are grateful for Exact Sciences’ commitment to supporting advocacy efforts to ensure people have timely access to screening, regardless of the test they choose," said Anjee Davis, President of Fight CRC. "It will allow us to empower a community of advocates across the country to impact meaningful policy change and ultimately bring us one step closer to a world without colorectal cancer."

Catalyst grants will help local leaders and advocates build the infrastructure and expertise needed to address these issues through policy change. Applications will be accepted from non-profit organizations (501(c)(3), 501(c)(4)), universities, and state and local coalitions. The program will be guided by an independent advisory council comprised of representatives including the American Cancer Society Cancer Action Network (ACS CAN) and the Prevent Cancer Foundation. The council reviews grant applications, selects recipients, and provides grant recipients with subject matter expertise. Fight CRC will award smaller Spark grants to additional organizations in other states to conduct action planning and help lay the foundation for success in future years. Fight CRC will announce the first Catalyst grant recipients in the coming weeks.

"Policy change is most effective when it’s driven by sound science. We are grateful that our partners at Exact Sciences and Fight CRC are teaming up to push for public policy changes at the state level that will increase screening rates for colorectal cancer," said Lisa Lacasse, president of ACS CAN. "We look forward to working collectively to ensure more and more Americans have access to covered colorectal cancer screening, free of any potential cost-sharing barriers, creating the opportunity to save more lives from colorectal cancer."

"Colorectal cancer is the second-leading cause of cancer death in the U.S. and the rising number of cases among those under the age of 45 is alarming," said Carolyn Aldigé, Founder and CEO, Prevent Cancer Foundation. "Because regular screenings are critical to reducing the risk of developing or dying from the disease, these Catalyst grants will go a long way toward helping states implement policy to increase access to colorectal cancer screening in accordance with appropriate screening guidelines. This is one cancer that can be stopped before it starts."

"Colorectal cancer is a pressing public health problem, despite it being one of the most preventable cancers. The Catalyst program taps into the best of all of us to get more people screened," said Kevin Conroy, chairman and CEO of Exact Sciences. "We are proud to stand shoulder to shoulder with Fight CRC to empower the grant recipients with the resources they need to remove barriers to screening."

Representatives from the inaugural grant recipients will participate in a training session as part of Fight CRC’s annual Call-on Congress, March 15-16. Grantees will share their goals and challenges and begin developing an action plan to achieve policy change in their state.

Concord Medical Welcomes RMB700 Million Investment

On March 11, 2020 Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specializing in cancer care, research, education and prevention by operating a network of medically advanced comprehensive cancer hospitals and standalone radiotherapy and diagnostic imaging centers in China, reported that CITIC Industrial Investment Group Limited, a renowned investment institution, will make an investment in Concord Medical’s subsidiary, Meizhong Jiahe Hospital Management Group Co., Ltd. ("Meizhong Jiahe"), subject to the satisfaction of closing conditions pursuant to an agreement entered into between the parties (Press release, Concord Medical Services Holdings, MAR 11, 2020, View Source [SID1234555440]). The total investment will be approximately RMB700 million.

As the most important operating platform of Concord Medical in China, Meizhong Jiahe is focusing on the development and management of comprehensive cancer hospitals and the standalone radiotherapy and diagnostic imaging center network in China. Meizhong Jiahe is committed to provide its patients with high-quality patient-centered multidisciplinary cancer care services. In addition, Meizhong Jiahe provides the cutting-edge Proton therapy treatment option in the Company’s Beijing, Shanghai and Guangzhou cancer hospitals. Meizhong Jiahe is dedicated to become a premier cancer medical services provider for the patients in China by helping to eradicate the cancer diseases by offering international recognized clinical research, multidisciplinary treatment care approach and advanced hospital management systems.

Dr. Jianyu Yang, Chairman and Chief Executive Officer of Concord Medical, commented, "We are excited and honored to have such a strong partner to make a significant investment in Meizhong Jiahe, which can support the opening of our Guangzhou Cancer Hospital this year and the operation of our other medical institutions. We are very confident that Meizhong Jiahe will continue to take this opportunity to invest in the healthcare industry in China and to introduce more state-of-the art medical technologies to our hospitals. We also believe that Meizhong Jiahe will offer the high-quality clinical outcomes and the world-class cancer care services to our patients."

Cannabics Pharmaceuticals Shows Specific Cultivars Identified to Have Positive Anti-Tumor Effects on Gastric Adenocarcinoma

On March 11, 2020 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, reported that it has completed a scan of selected RCKMC’s cannabis strains. Results obtained have shown that two specific strains have demonstrated higher anti-tumor activity (Press release, Cannabics Pharmaceuticals, MAR 11, 2020, View Source [SID1234555438]).

Cells monitored for 48h using fluorescent microscopy. AGS cells were treated with Extract of CNBX-RCK cannabis plant 802-2. Cells were stained with nuclear dye (blue) and cell death (yellow).
Cells monitored for 48h using fluorescent microscopy. AGS cells were treated with Extract of CNBX-RCK cannabis plant 802-2. Cells were stained with nuclear dye (blue) and cell death (yellow).
The strains were examined at the company’s High Throughput Screening (HTS) facility located in Israel, in which their anti-tumor properties were examined on a wide range of cancers. Analysis of the scans revealed specific cultivars which have a more significant necrotic effect on Gastric Adenocarcinoma cells.

The results will be used to further breed the selected cultivars for specific cancers, focusing on Gastric cancers. The cultivars to be developed will be the source for active pharmaceutical ingredients (API’s) for future clinical studies.

About RCKMC

RCK is an Israeli cannabis company, breeding tailor-made medical strains and repeatable & stable cannabis hybrid-seeds, being the first company to operate a methodological marker-assisted-breeding of cannabis, having cutting-edge proprietary technologies and led by professional team, RCKMC opens the gate to a new era of cannabis agriculture.

Universal Health Services, Inc. To Present In Virtual Barclays Global Healthcare Conference

On March 11, 2020 Universal Health Services, Inc. (NYSE: UHS) reported that Steve Filton, Executive Vice President and Chief Financial Officer will present at the virtual Barclays Global Healthcare Conference on Thursday, March 12, 2020 at 10:45am (Press release, Universal Health Services, MAR 11, 2020, View Source [SID1234555437]). A live audio webcast of the presentation will be available on the Company’s website (www.uhsinc.com). For those unable to listen to the live webcast, a replay will be available on the Company’s website for 90 days following the conferences.

Universal Health Services (NYSE: UHS) is one of the largest and most respected hospital management companies in the nation. For over 40 years, UHS and its affiliates have focused on meeting patients’ healthcare needs across hundreds of local communities. Today, UHS subsidiaries own and/or operate 398 inpatient and outpatient facilities including acute care hospitals, behavioral health facilities, ambulatory centers, freestanding emergency departments, and urgent care centers in 37 states, Washington, D.C., the United Kingdom and Puerto Rico. For additional information on the Company, visit our web site: View Source